CO2018002046A2 - Nueva composición oral de libreación retardada dual de dexlansoprazol - Google Patents

Nueva composición oral de libreación retardada dual de dexlansoprazol

Info

Publication number
CO2018002046A2
CO2018002046A2 CONC2018/0002046A CO2018002046A CO2018002046A2 CO 2018002046 A2 CO2018002046 A2 CO 2018002046A2 CO 2018002046 A CO2018002046 A CO 2018002046A CO 2018002046 A2 CO2018002046 A2 CO 2018002046A2
Authority
CO
Colombia
Prior art keywords
dexlansoprazole
oral
pharmaceutically acceptable
new
release layer
Prior art date
Application number
CONC2018/0002046A
Other languages
English (en)
Inventor
Anwar Siraj Daud
Shamsuddin Jamaluddin
Original Assignee
Zim Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57884420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018002046(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zim Laboratories Ltd filed Critical Zim Laboratories Ltd
Publication of CO2018002046A2 publication Critical patent/CO2018002046A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Abstract

La presente descripción proporciona una composición farmacéutica oral de liberación retardada dual de Dexlansoprazol o sales farmacéuticamente aceptables o formas hidratadas del mismo. La composición farmacéutica de liberación retardada dual descrita puede incorporar dos formulaciones de liberación pulsátil (a) y (b), en donde la formulación (a) puede incluir: (i) una partícula de núcleo que comprende Dexlansoprazol o una sal farmacéuticamente aceptable o un hidrato del mismo, y (ii) una capa de liberación controlada dependiente del pH; y la formulación (b) puede incluir: (i) una partícula de núcleo que comprende Dexlansoprazol o una sal farmacéuticamente aceptable o un hidrato del mismo, (ii) una capa de liberación controlada independiente del pH, y (iii) una capa de liberación controlada dependiente del pH.
CONC2018/0002046A 2015-07-28 2018-02-26 Nueva composición oral de libreación retardada dual de dexlansoprazol CO2018002046A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2851MU2015 2015-07-28
PCT/IB2016/054467 WO2017017615A1 (en) 2015-07-28 2016-07-27 Novel dual delayed release oral composition of dexlansoprazole

Publications (1)

Publication Number Publication Date
CO2018002046A2 true CO2018002046A2 (es) 2018-02-28

Family

ID=57884420

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0002046A CO2018002046A2 (es) 2015-07-28 2018-02-26 Nueva composición oral de libreación retardada dual de dexlansoprazol

Country Status (6)

Country Link
EP (1) EP3328364A4 (es)
BR (1) BR112018001539A2 (es)
CL (1) CL2018000220A1 (es)
CO (1) CO2018002046A2 (es)
PE (1) PE20181012A1 (es)
WO (1) WO2017017615A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111991367A (zh) * 2020-09-21 2020-11-27 青岛吉达巴尔国际贸易有限公司 一种埃索美拉唑镁脉冲微丸胶囊剂及制备方法
KR102471545B1 (ko) * 2020-11-20 2022-11-29 서울대학교 산학협력단 덱스란소프라졸을 유효성분으로 포함하는 pH 의존성 타블렛-인-캡슐 복합제제 및 이의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117756A2 (en) * 2009-03-31 2010-10-14 Dr. Reddy's Laboratories Ltd Substituted benzimidazole pharmaceutical formulations
US20120058194A1 (en) * 2010-08-27 2012-03-08 Navin Vaya Pharmaceutical formulations comprising substituted benzimidazole derivatives
WO2013111149A1 (en) * 2011-12-21 2013-08-01 Hetero Research Foundation Controlled release solid oral compositions of dexlansoprazole

Also Published As

Publication number Publication date
BR112018001539A2 (pt) 2018-09-18
EP3328364A1 (en) 2018-06-06
WO2017017615A1 (en) 2017-02-02
EP3328364A4 (en) 2019-01-02
PE20181012A1 (es) 2018-06-26
CL2018000220A1 (es) 2018-07-20

Similar Documents

Publication Publication Date Title
HRP20201812T1 (hr) Modulatori proteina jezgre hepatitisa b
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
BR112018071585A2 (pt) formulações de um inibidor de lsd1
UY35933A (es) Composiciones farmacéuticas que comprenden azd9291
EA201792116A1 (ru) Ингибитор янус-киназы
CL2017003320A1 (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
CO2018005842A2 (es) Composición farmacéutica que comprende un potente inhibidor de urat 1
AR096543A1 (es) INHIBIDORES DE QUINASA PI3 d Y g SELECTIVOS DUALES
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CR20170314A (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
UY36124A (es) Derivados de carboxamida
AR092356A1 (es) Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
CO2018002046A2 (es) Nueva composición oral de libreación retardada dual de dexlansoprazol
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
EP3530654A4 (en) CARBOXYLIC ACID COMPOUND WITH QUINOLINYL SUBSTITUTE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
GT201400094A (es) Formulación de liberación inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)-fenil]-benzamida
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
AR103219A1 (es) Compuesto de (1h-indol-3-il)propan-1-ona, composición farmacéutica, combinación y mezcla que lo comprenden y su uso para la fabricación de un medicamento
AR124515A2 (es) 2-(1-(9h-purin-6-ilamino)propil)-3-(3-fluorofenil)-4h-cromen-4-ona y (s)-2-(1-(9h-purin-6-ilamino)propil)-3-(3-fluorofenil)-4h-cromen-4-ona, composición farmacéutica; métodos relacionados, y uso de dichos compuestos para fabricar medicamentos